AbCellera Biologics Profit Margin

The latest profit margin for ABCL is -248.82% as of June 2026. That compares with -503.91% in the prior-year period — up 50.6% year over year. That is below the sector sector average of 21.34%. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABCL's profit margin moved from -503.91% to -248.82% — a 50.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbCellera Biologics's valuation or profitability profile.

Against its sector companies, ABCL currently prints -248.82% for profit margin, while the sector average sits near 21.34%. That is roughly 1265.9% below the sector mean. Large gaps often invite a closer look at AbCellera Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively AbCellera Biologics converts resources into returns. At -248.82%, ABCL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -503.91% in the prior-year period — up 50.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ABCL's profit margin (-248.82%), review year-over-year change from -503.91%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.